Topical tazarotene cream (0.1%) in the treatment of facial acne: an open clinical trial
| Autor: | H K Paul, A M Choudhury, A. S. M. Zakaria, Mohammad Tariqul Islam, Mohammed Atiqur Rahman |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Severity of Illness Index Young Adult Tazarotene Severity of illness Acne Vulgaris medicine Humans Prospective Studies Prospective cohort study Acne business.industry Nicotinic Acids Treatment options General Medicine Topical tazarotene medicine.disease Dermatology Clinical trial Treatment Outcome Face Female Dermatologic Agents Keratinocyte differentiation business medicine.drug |
| Zdroj: | Bangladesh Medical Research Council bulletin. 36(2) |
| ISSN: | 0377-9238 |
| Popis: | Background: Tazarotene is a new 3rd generation topical acetylenic retinoid. It normalizes keratinocyte differentiation, reduces keratinocyte proliferation and decreases expression of inflammatory markers. Tazarotene was approved by US FDA in 1997 for acne vulgaris. Objectives: To evaluate the efficacy and safety of topical tazarotene 0.1% cream in the treatment of facial acne. Materials and methods: 67 patients with facial acne in the age range of 13-30 years were enrolled in the study. Purposive sampling was done. Patients were treated with topical Tazarotene cream (0.1%) and were instructed to apply the medication as a thin film over the affected area in the evening once daily for 12 weeks. Follow-up was done at 2nd, 4th week, 8th week and at 12th week. Results: Of the 67 patients, 53% got remission, 9% had good response, 34% had poor response and there was no response in 4% of the patients by 12 weeks of treatment. Among the patients, 9 (13.43%) developed mild side effects. Conclusion: Topical tazarotene cream (0.1%) is a effective and safe treatment option for acne vulgaris affecting face. It is mostly effective in grade-1 and grade-2 acne. DOI: 10.3329/bmrcb.v36i2.6985 Bangladesh Med Res Counc Bull 2010; 36: 43-46 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|